Third line Treatment in Relapsed/Refractory Hodgkin's Lymphoma and Aggressive non-Hodgkin Lymphoma after 2nd line ESHAP or GEMOX

Efficacy and toxicity of gemcitabine/ dexamethasone / carboplatin versus ESHAP protocol in treatment of relapsed/ refractory Non-Hodgkin’s lymphomas (NHL)

Outcome of Second Line Chemotherapy (Gemcitabine, Dexamethasone, and Cisplatin) in Relapsed and Refractory Non Hodgkin Lymphoma

Liposomal Doxorubicin based Chemotherapy in the treatment of Relapsed Diffuse Large B-cell Lymphoma

Bendamustine in Refractory / Relapsed Non Hodgkin Lymphoma

Relapse in Patients with Non-Hodgkin’s Lymphpma

Long Term Outcomes of Relapsed/Refractory Non-Hodgkin Lymphoma:
A Single Center Experience

COMPARISON BETWEEN CALGB 8811 PROTOCOL AND DFCI PROTOCOL IN ALL PATIENTS REGARDING THE RATE OF INFECTION AND COMPLETE REMISSION

Phase II randomized study between CHOP-14 and CHOEP-21 in the management of adult aggressive Non Hodgkin's Lymphoma at NEMROCK

Early Complete Response after Chemotherapy as A Prognostic Indicator for Final Outcome in High Grade Non-Hodgkin’s Lymphoma Patients